(2S)-1-methylpyrrolidine-2-carbonyl chloride | 911281-86-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-1-methylpyrrolidine-2-carbonyl chloride
• CAS: 911281-86-2
• 化学式: C₆H₁₀ClNO
• 分子量: 147.605
• InChiKey: NJSQADKUMGVESS-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[(1R)-1-(3,5-Difluorophenyl)ethyl]prop-2-en-1-amine 、 (2S)-1-methylpyrrolidine-2-carbonyl chloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  (E)-Alkenes as replacements of amide bonds: Development of novel and potent acyclic CGRP receptor antagonists

  摘要：

  A new class of CGRP receptor antagonists was identified by replacing the central amide of a previously identified anilide lead structure with ethylene, ethane, or ethyne linkers. (E)-Alkenes as well as alkynes were found to preserve the proper bioactive conformation of the amides, necessary for efficient receptor binding. Further exploration resulted in several potent compounds against CGRP-R with low susceptibility to P-gp mediated efflux. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.11.027

文献信息

• Hydroxamate-Based Inhibitors of Deacetylases
  申请人：BROOKS Clinton A.

  公开号：US20110060009A1

  公开（公告）日：2011-03-10

  The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , ring A, and Z are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of use compounds of Formula I in treating pathologic conditions or disorders mediated wholly or in part by deacetylases.

  本教导涉及Formula I的化合物：及其药用盐、水合物、酯和前药，其中R1、R2、R3、R4、R5、环A和Z的定义如本文所述。本教导还提供制备Formula I化合物的方法，以及利用Formula I化合物治疗完全或部分由去乙酰酶介导的病理状况或疾病的方法。
• HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES
  申请人：Brooks Clinton Alan

  公开号：US20130231373A1

  公开（公告）日：2013-09-05

  The present teachings relate to compounds of Formula (I): and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , ring A, and Z are as defined herein. The present teachings also provide methods of preparing compounds of Formula (I) and methods of use compounds of Formula (I) in treating pathologic conditions or disorders mediated wholly or in part by deacetylases.

  本发明涉及公式（I）化合物及其药学上可接受的盐、水合物、酯和前药，其中R1、R2、R3、R4、R5、环A和Z的定义如本文所述。本发明还提供制备公式（I）化合物的方法，以及使用公式（I）化合物治疗完全或部分通过去乙酰化酶介导的病理条件或疾病的方法。
• NMDA Receptor Modulators and Uses Thereof
  申请人：Northwestern University

  公开号：US20150315237A1

  公开（公告）日：2015-11-05

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本发明涉及具有增强的NMDA受体活性调节功效的化合物。这些化合物可用于治疗疾病和障碍，如学习、认知活动和镇痛，特别是在缓解和/或减轻神经病理性疼痛方面。本发明还揭示了口服制剂和其他药学上可接受的化合物递送形式，包括静脉注射制剂。
• SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
  申请人：Apytinyx Inc.

  公开号：US20180127430A1

  公开（公告）日：2018-05-10

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
• NDMA RECEPTOR MODULATORS AND USES THEREOF
  申请人：Northwestern University

  公开号：US20190135862A1

  公开（公告）日：2019-05-09

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.